-transparent.png){kind=logo}
A series of murine thymic lymphoma cell sublines was selected in vitro for resistance to cis-diamminedichloroplatinum(II) (CDDP). The level of CDDP resistance correlated with reduced drug accumulation in these cells. A rabbit antiserum was raised against the plasma membrane of a CDDP-resistant subline and used in Western blot analyses. Increased expression of a surface antigen of approximately 200 kDa was observed and found to correlate with the degree of resistance. Further biochemical and immunological studies demonstrated that this is a plasma membrane glycoprotein. However, it is different from the multidrug resistance-associated P-glycoprotein with a molecular weight of about 170,000. We have called this unique CDDP resistance-associated membrane protein CPR-200.
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
August 1991,
The Biochemical journal,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
January 1991,
International journal of cancer,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
July 1992,
[Hokkaido igaku zasshi] The Hokkaido journal of medical science,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
June 1988,
Cancer research,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
December 1988,
Cancer letters,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
December 1987,
Cancer research,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
January 1995,
Cancer chemotherapy and pharmacology,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
June 1986,
In vitro cellular & developmental biology : journal of the Tissue Culture Association,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
January 1988,
Cancer letters,
K Kawai, and
N Kamatani, and
E Georges, and
V Ling
January 1988,
Cancer research,
